Colivelin

Colivelin's neuroprotective effects are primarily mediated through potent activation of Signal Transducer and Activator of Transcription 3 (STAT3). Binding to gp130 co-receptors triggers JAK-STAT3 phosphorylation, upregulating anti-apoptotic genes including Bcl-2 and Bcl-xL. This cascade suppresses neuronal apoptosis provoked by amyloid-beta oligomers, presenilin-1 mutations, and other Alzheimer's-associated stressors.

By fusing ADNF's SALLRSIPA core with Humanin sequences, Colivelin achieves neuroprotection at femtomolar concentrations in cell culture, substantially lower than either parent compound. The dual-domain structure likely enables simultaneous engagement of STAT3 and complementary survival pathways, producing a synergistic rather than merely additive effect.

Transgenic AD mouse studies show Colivelin preserves spatial memory in the Morris water maze and reduces hippocampal neuronal loss after subcutaneous administration. The peptide prevented memory deficits caused by presenilin-2 mutations and intracerebroventricular amyloid-beta injections in multiple independent mouse models.

Studies in ALS model mice (SOD1 mutants) report extended survival and delayed motor dysfunction onset following Colivelin treatment. These findings expanded interest beyond Alzheimer's to broader motor neuron disease research.

Cell culture studies demonstrate protection against diverse death stimuli including oxidative stress, glutamate excitotoxicity, and ER stress at picomolar to femtomolar concentrations. No human clinical trials have been conducted.